French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, t…
Tesla Motors, which went public with much fanfare last June, nearly tripled its losses for 2010 as it invested heavily to engineer and get ready for producing the Model S, its second offering and the first that targets a broade…
Cisco’s latest earnings topped analysts’ estimates, but profit margins disappointed investors, and the stock plunged 15%. CEO John Chambers insists it’s only temporary and that better days are coming. So far, though, nobody is …
After a holiday season that marked a return to some form of normalcy, merchants are bracing for a year of mild sales growth and more stable operations. Whether that momentum holds is an open question, given the state of the hou…
The market heads into a busy week of economic reports and the end of fourth-quarter earnings season primed for yet more gains. After all, if traders could sustain the rally through 18 days of Egyptian turmoil, a return to keyin…